Walpar Nutritions Ltd
Incorporated in 2009, Walpar Nutrition Ltd develops and manufactures various pharmaceutical products.[1]
- Market Cap ₹ 38.3 Cr.
- Current Price ₹ 40.8
- High / Low ₹ 53.3 / 37.7
- Stock P/E 24.2
- Book Value ₹ 17.0
- Dividend Yield 0.00 %
- ROCE 17.6 %
- ROE 11.9 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company's working capital requirements have reduced from 55.2 days to 39.1 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 8.07% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Dec 2020 1m | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 16.71 | 1.43 | 6.07 | 26.76 | 28.70 | 51.31 | 60.16 | 63.97 | |
| 15.50 | 1.05 | 5.61 | 25.68 | 27.92 | 49.54 | 57.32 | 61.30 | |
| Operating Profit | 1.21 | 0.38 | 0.46 | 1.08 | 0.78 | 1.77 | 2.84 | 2.67 |
| OPM % | 7.24% | 26.57% | 7.58% | 4.04% | 2.72% | 3.45% | 4.72% | 4.17% |
| 0.00 | 0.00 | 0.00 | 0.02 | 0.27 | 0.13 | 0.10 | 0.15 | |
| Interest | 0.73 | 0.05 | 0.18 | 0.48 | 0.34 | 0.21 | 0.10 | 0.06 |
| Depreciation | 0.29 | 0.02 | 0.12 | 0.28 | 0.25 | 0.21 | 0.41 | 0.47 |
| Profit before tax | 0.19 | 0.31 | 0.16 | 0.34 | 0.46 | 1.48 | 2.43 | 2.29 |
| Tax % | 36.84% | 25.81% | 6.25% | -26.47% | 34.78% | 24.32% | 30.45% | |
| 0.12 | 0.23 | 0.15 | 0.42 | 0.29 | 1.11 | 1.69 | 1.58 | |
| EPS in Rs | 0.38 | 0.22 | 0.46 | 0.32 | 1.18 | 1.80 | 1.68 | |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 31% |
| TTM: | 26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 70% |
| 3 Years: | 58% |
| TTM: | -20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 5% |
| 1 Year: | -18% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 8% |
| Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.93 | 3.00 | 3.34 | 4.54 | 4.54 | 4.70 | 9.39 | 9.39 |
| Reserves | 0.00 | 0.23 | 1.44 | 6.49 | 6.78 | 8.64 | 5.63 | 6.62 |
| 5.55 | 5.88 | 5.46 | 4.38 | 3.21 | 0.32 | 0.00 | 0.21 | |
| 5.69 | 5.44 | 5.45 | 7.95 | 7.33 | 9.84 | 15.90 | 18.85 | |
| Total Liabilities | 13.17 | 14.55 | 15.69 | 23.36 | 21.86 | 23.50 | 30.92 | 35.07 |
| 1.12 | 1.15 | 1.07 | 0.94 | 0.83 | 1.48 | 2.29 | 2.49 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.03 | 0.04 |
| Investments | 0.00 | 0.00 | 0.06 | 2.93 | 2.84 | 4.70 | 4.70 | 5.06 |
| 12.05 | 13.40 | 14.56 | 19.49 | 18.17 | 17.30 | 23.90 | 27.48 | |
| Total Assets | 13.17 | 14.55 | 15.69 | 23.36 | 21.86 | 23.50 | 30.92 | 35.07 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| -0.76 | 0.40 | 1.38 | -0.32 | 1.09 | 3.13 | 2.71 | |
| -0.66 | 0.00 | -0.70 | -4.58 | 0.46 | -0.88 | -1.23 | |
| 1.07 | -0.24 | -0.06 | 4.27 | -1.52 | -2.18 | -0.42 | |
| Net Cash Flow | -0.35 | 0.17 | 0.62 | -0.63 | 0.03 | 0.07 | 1.06 |
| Free Cash Flow | -1.24 | 0.40 | 1.37 | -0.48 | 0.94 | 2.28 | 1.48 |
| CFO/OP | -63% | 105% | 300% | -23% | 150% | 183% | 107% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 160.55 | 2,141.50 | 430.54 | 124.26 | 111.66 | 71.78 | 102.84 |
| Inventory Days | 130.73 | 1,690.75 | 369.26 | 103.22 | 89.87 | 39.99 | 32.83 |
| Days Payable | 186.46 | 2,156.44 | 434.08 | 130.02 | 99.69 | 67.10 | 93.80 |
| Cash Conversion Cycle | 104.82 | 1,675.81 | 365.73 | 97.45 | 101.84 | 44.67 | 41.87 |
| Working Capital Days | 60.07 | 1,028.64 | 268.79 | 79.79 | 79.99 | 46.31 | 39.13 |
| ROCE % | 3.84% | 6.55% | 5.34% | 11.56% | 17.64% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Domestic Sales Revenue Rs. in Lakhs |
|
||||
| Employee Benefit Expenses Rs. in Lakhs |
|||||
| Export Sales Revenue Rs. in Lakhs |
|||||
| Trade Receivables Turnover Ratio times |
|||||
Extracted by Screener AI
Documents
Announcements
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
8 April 2026 - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026; no physical shares received for dematerialization.
-
Structural Digital Database
8 April 2026 - Submitted SDD compliance certificate for quarter ended 31 March 2026; no non-compliance observed.
-
Structural Digital Database
8 April 2026 - Submitted FY2025-26 SDD compliance certificate; no non-compliance reported.
-
Trading Window
28 March 2026 - Trading window closed from 1 Apr 2026 until 48 hours after audited results for year/half-year ended 31 Mar 2026.
-
Outcome of Board Meeting
20 March 2026 - Board approved corporate guarantee to SIDBI for Walpar Wellness's Rs.5,64,05,000 term loan (20 Mar 2026).
Business Overview:[1][2]
WNL is in the business of manufacturing and trading of Pharmaceutical, Nutraceutical, Herbal, and Ayurvedic Products. The company has a presence across 42+ countries and has served 650+ clients.